MRC1 and colorectal carcinoma: Further analysis of outcome data from the QUASAR trial by Hutchins et al. demonstrated improved prognosis and lower risk of recurrence of CRC in patients with dMMR, with an 11% recurrence rate in dMMR, compared to a 26% recurrence rate in patients with no mutations or deficiencies in MMR; nonetheless, it was not predictive of chemotherapy response [47,48].